Stay updated on Resmetirom in NASH and Fibrosis Clinical Trial
Sign up to get notified when there's something new on the Resmetirom in NASH and Fibrosis Clinical Trial page.

Latest updates to the Resmetirom in NASH and Fibrosis Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedNew help sections were added (How to Read a Study Record, Common Questions, How to Join a Study) and the Intervention/Treatment heading was standardized. Recruitment status now indicates No longer looking for participants, and the page revision was updated to v3.6.0.SummaryDifference0.1%

- Check15 days agoChange DetectedNew site at St. Luke's Hospital Of Kansas City in Missouri has been added and the study's total locations updated to 247. Tom Hare is now listed as Study Director, and Rebecca Taub, MD is no longer listed.SummaryDifference0.2%

- Check30 days agoChange DetectedA new footer revision tag 'Revision: v3.5.4' has been added, replacing 'Revision: v3.5.3'. This indicates an update to the page's revision history.SummaryDifference0.0%

- Check37 days agoChange DetectedNew trial sites were added in Roma, Milano, Palermo, Novara, Messina and Brussels Capital in Belgium, along with Budapest. Some previously listed locations were removed or reformatted (e.g., Brussels, Belgium; Messina, Italy; Novara, Italy) to reflect updated site naming.SummaryDifference0.9%

- Check51 days agoChange DetectedA new revision label v3.5.3 was added, replacing the previous v3.5.2 in the page header. This indicates an internal update to the page version without altering visible content.SummaryDifference0.0%

- Check60 days agoChange DetectedThe page now lists the Vienna location with the more specific label “State of Vienna, Vienna, Austria.” The displayed site revision/version number has also been updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

Stay in the know with updates to Resmetirom in NASH and Fibrosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Resmetirom in NASH and Fibrosis Clinical Trial page.